At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 15 enrolled

Drug / intervention

Secukinumabdrug

Likely dose

Secukinumab 300mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02592018

NCT02592018Phase 4Completed

Compare CT.gov

Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling

University of California, San Francisco·interventional·Posted Oct 30, 2015·Updated Sep 16, 2020

In Brief

A Phase 4 clinical trial evaluating Secukinumab for Psoriasis. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPsoriasis

CountriesUnited States

CollaboratorsNovartis Pharmaceuticals

Timeline

Phase 4CompletedFinished

20162017201820192020202120222023202420252026

First PostedOct 2015

Enrollment StartOct 2016

Primary CompletionDec 2018

TodayJul 2026

First PostedOct 30, 2015

Enrollment StartOct 1, 2016

Primary CompletionDec 1, 2018

TodayJul 2, 2026

Enrollment to primary: 2.2 yearsPosted 10.7 years ago

Interventions

Secukinumabdrug

Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.